Literature DB >> 19803537

Budget-impact analyses: a critical review of published studies.

Ewa Orlewska1, Laszlo Gulácsi.   

Abstract

This article reviews budget-impact analyses (BIAs) published to date in peer-reviewed bio-medical journals with reference to current best practice, and discusses where future research needs to be directed. Published BIAs were identified by conducting a computerized search on PubMed using the search term 'budget impact analysis'. The years covered by the search included January 2000 through November 2008. Only studies (i) named by authors as BIAs and (ii) predicting financial consequences of adoption and diffusion of a new health intervention(s) within a specific healthcare setting were included. Relevant studies were evaluated according to the checklist that focuses on issues unique to BIA, highlighting areas of agreement or dissent between published studies and methodological guidelines. A total of 34 studies met the inclusion criteria, the majority published in 2007-8. Of these, 41% were from the US, 54% were prepared for pharmaceuticals and 65% had BIA as their main aim. The published BIAs were heterogeneous in respect of methods for deriving budget-impact estimates, time horizon and population. There is fairly good agreement between published studies and methodological guidelines within the scope of perspective, comparator, cost included and data sources. Specific issues that need to be addressed and/or improved are reporting format, sensitivity analysis and discounting. The results indicate that, recently, BIAs have appeared more frequently in peer-reviewed journals, providing stimulus to development, validation and dissemination of methods. Many published studies fail to reach the desired quality, but this situation should change with good research practice principles that will help codify and clarify important issues and promote standardization and transparency. Future research needs to be directed to quality assurance of published BIAs and investment in data collection for parameters specific to BIAs.

Entities:  

Mesh:

Year:  2009        PMID: 19803537     DOI: 10.2165/11313770-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  41 in total

1.  Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium.

Authors:  Lieven Annemans; Ralph Crott; Diana Degraeve; Dominique Dubois; Michel Huybrechts; Frank Peys; Hugo Robays; Jean Smets; Marc Tomas; Kathleen Vanschoubroek
Journal:  Pharm World Sci       Date:  2002-02

2.  Prevalence-based economic evaluation.

Authors:  J Mauskopf
Journal:  Value Health       Date:  1998-11       Impact factor: 5.725

3.  The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.

Authors:  Brennan M R Spiegel; Gareth S Dulai; Brian S Lim; Neel Mann; Fasiha Kanwal; Ian M Gralnek
Journal:  Clin Gastroenterol Hepatol       Date:  2006-07-17       Impact factor: 11.382

4.  [Economic impact of the taxus coronary stent: implications for the Spanish healthcare system].

Authors:  Stephen Russell; Fernando Antoñanzas; Vicente Mainar
Journal:  Rev Esp Cardiol       Date:  2006-09       Impact factor: 4.753

5.  Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis.

Authors:  Robert Launois; Stéphanie Payet; Nathalie Saidenberg-Kermanac'h; Camille Francesconi; Lionel Riou França; Marie-Christophe Boissier
Journal:  Joint Bone Spine       Date:  2008-10-31       Impact factor: 4.929

6.  Modelling the resource implications and budget impact of new reimbursement guidelines for the management of cow milk allergy in Finland.

Authors:  Julian F Guest; Erkka Valovirta
Journal:  Curr Med Res Opin       Date:  2008-03-13       Impact factor: 2.580

7.  Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers.

Authors:  Anderson W Chuck; David Hailey; Philip Jacobs; Douglas C Perry
Journal:  Int J Technol Assess Health Care       Date:  2008       Impact factor: 2.188

8.  Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.

Authors:  Mark D Danese; Carolina Reyes; Kelly Northridge; Deborah Lubeck; Chin-Yu Lin; Paula O'Connor
Journal:  Clin Ther       Date:  2008-04       Impact factor: 3.393

9.  [Budgetary impact of pneumococcal conjugate vaccination of newborns].

Authors:  P Berto; D Gallio; N Principi
Journal:  Ann Ig       Date:  2007 May-Jun

10.  Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients.

Authors:  Negro Roberto Dal; M Eandi; L Pradelli; S Iannazzo
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more
  15 in total

1.  Pharmacoeconomic evaluation in Ireland: a review of the process.

Authors:  Lesley Tilson; Aisling O'Leary; Cara Usher; Michael Barry
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Budget impact analysis in economic evaluation: a proposal for a clearer definition.

Authors:  Livio Garattini; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2011-12

Review 3.  A Methodological Review of US Budget-Impact Models for New Drugs.

Authors:  Josephine Mauskopf; Stephanie Earnshaw
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

Review 4.  The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA).

Authors:  Salah Ghabri; Erwan Autin; Anne-Isabelle Poullié; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2018-04       Impact factor: 4.981

5.  The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.

Authors:  László Gulácsi; Valentin Brodszky; Petra Baji; Fanni Rencz; Márta Péntek
Journal:  Adv Ther       Date:  2017-04-10       Impact factor: 3.845

6.  Budget Impact Analysis of Switching to Rituximab's Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa.

Authors:  Ammar Almaaytah
Journal:  Clinicoecon Outcomes Res       Date:  2020-09-15

7.  Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study.

Authors:  Anna Hung; Julia F Slejko; Amy Lugo; Fadia Shaya; Stuart T Haines; C Daniel Mullins
Journal:  J Manag Care Spec Pharm       Date:  2019-08

8.  Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.

Authors:  Anna Hung; C Daniel Mullins; Julia F Slejko; Stuart T Haines; Fadia Shaya; Amy Lugo
Journal:  J Manag Care Spec Pharm       Date:  2019-03

9.  "Budget impact analyses": a practical policy making tool for drug reimbursement decisions.

Authors:  Hamid Reza Jamshidi; Naghmeh Foroutan; Jamshid Salamzadeh
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

10.  Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.

Authors:  Valentin Brodszky; Petra Baji; Orsolya Balogh; Márta Péntek
Journal:  Eur J Health Econ       Date:  2014-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.